Retail News CRM

Tag: incepta pharmaceuticals

  • Bangladesh Drugmakers See Little Gain from US 100% Tariff Exemption

    Bangladesh Drugmakers See Little Gain from US 100% Tariff Exemption

    Bangladesh’s pharmaceutical industry will see limited immediate export gains from a US tariff adjustment exempting specialty medicines, according to industry leaders including Shawkat Haider of Beximco Pharmaceuticals Limited.

    Under Section 232 of the Trade Expansion Act, the US announced a 100 percent ad valorem tariff on certain licensed pharmaceutical products and ingredients from September 29, while granting zero-tariff entry on selected specialty drugs to eligible jurisdictions.

    The zero-rate list covers rare-disease orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, and antibody-drug conjugates from approved partners including Bangladesh, India, Japan, and the European Union.

    The Manufacturing Gap

    Exemption on paper means little without production lines on the ground. Bangladesh built its drug export trade on generic small-molecule tablets, capsules and basic formulations rather than complex biologics.

    Commercial production of gene therapies or antibody-drug conjugates requires sterile cleanrooms, specialized bioreactors and years of clinical validation. Shawkat Haider, executive director of Beximco Pharmaceuticals Limited, confirmed the structural limitation facing domestic producers.

    “Bangladesh will not get any significant benefit from the tariff adjustment because we do not manufacture this type of highly sophisticated medicine,” Haider said.

    Regional Competition and Compliance

    Regional competitors hold a wide lead in the specialty segments covered by the US order. Contract manufacturers in South Korea and India already operate US Food and Drug Administration-cleared biologic plants. They supply licensed ingredients directly to North American distributors.

    Local producers attempting to enter these niches face steep capital costs and strict US regulatory audits. Domestic veterinary medicine manufacturers also lack the international certifications needed to clear US border inspections, leaving that market segment out of reach for now.

    Earlier Tariffs and Trade Timelines

    The revised pharmaceutical duties follow an earlier round of US trade enforcement under Section 232. Washington activated the first phase of 100 percent tariffs on July 31 for an initial annex of listed companies before widening enforcement to broader pharmaceutical categories on September 29.

    Industry lobby BAPI, the Bangladesh Association of Pharmaceutical Industries, is reviewing product lists to identify whether any existing formulation pipelines qualify under the zero-tariff rules. Abdul Muktadir, president of BAPI and chairman of Incepta Pharmaceuticals, said individual product assessments will determine if future export openings exist.

    What to Watch

    Dhaka drugmakers are reviewing capital expenditure plans for dedicated biotech and oncology plants to evaluate their long-term viability under US export specifications.

    Government trade officials are tracking whether the US Trade Representative adds conventional oral generic categories to future Section 232 exemption schedules before the next tariff review cycle opens in 2027.

  • Bangladesh Power Shortages Force Consumer Goods Makers to Cut Factory Output

    Bangladesh Power Shortages Force Consumer Goods Makers to Cut Factory Output

    Bangladeshi consumer goods, food, and apparel manufacturers are cutting factory output and rescheduling shifts as industrial gas pressure drops by two thirds across major production hubs.

    The supply squeeze, triggered by an offshore liquefied natural gas terminal going offline on July 21, has forced plants onto costly diesel generators and raised operating expenses by up to 15 percent.

    Export Delays and Rising Fuel Costs

    Food and snack producers face immediate export disruptions. Bombay Sweets missed 45.47 percent of its export orders in August because of low gas pressure, leaving 113,000 dollars in paid orders undelivered while container freight rates to the Middle East reached 8,500 to 12,000 dollars.

    Diversified conglomerate PRAN-RFL Group has cut capacity on select processing lines in Narsingdi, Habiganj, Gazipur, and Narayanganj. The company is using liquefied petroleum gas to keep priority machinery running while idling others during pressure drops.

    Household goods supplier ACI Consumer Brands reports that running diesel generators for continuous 24-hour operations has increased production costs by 10 to 15 percent. Foreign buyers and domestic retail channels have resisted absorbing the difference, leaving manufacturers to absorb the margin squeeze.

    For regional retail brands sourcing apparel and packaged goods across South Asia, the bottlenecks demonstrate the fragility of grid-dependent production hubs, where sudden utility shortfalls directly jeopardize delivery timetables.

    Solar Investments to Offset Grid Failures

    Garment exporter Newage Group has altered shift patterns around electricity availability while drawing 25 percent of its plant power from rooftop solar installations. Drugmaker Incepta Pharmaceuticals is now juggling four distinct energy sources, grid electricity, natural gas, LPG, and diesel, to keep medicine lines operational.

    PRAN-RFL currently generates 35 to 38 megawatts of captive renewable power toward its 200-megawatt plant demand, with plans to expand solar generation capacity to 100 megawatts before the end of the fiscal year.